Research
Publications

Full list of publications 2014-2019

Verkarre V, Bibeau F [The inherited cancers, the pathologist]. Ann Pathol. 2020;40(2):61-62. doi:10.1016/j.annpat.2020.02.016

Cohen R, Pudlarz T, Garcia-Larnicol M-L, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]. Bull Cancer. 2020;107(4):438-446. doi:10.1016/j.bulcan.2019.11.016

Latorzeff I, Sargos P, Créhange G, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]. Cancer Radiother. Feb 11, 2020. doi:10.1016/j.canrad.2019.06.018

Maria A, Bourgier C, Martinaud C, Borie R, Rozier P, Rivière S, Crestani B, Guilpain P [From fibrogenesis towards fibrosis: Pathophysiological mechanisms and clinical presentations]. Rev Med Interne. Feb 08, 2020. doi:10.1016/j.revmed.2020.01.002

Adenis A, Samalin E, Mazard T, Portales F, Mourregot A, Ychou M [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?]. Bull Cancer. Jan 21, 2020. doi:10.1016/j.bulcan.2019.12.005

Gros L, Paturel C, Perrot I, Bensussan A, Eliaou J-F, Bastid J, Bonnefoy N [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response]. Med Sci (Paris). 2020;36(2):112-115. doi:10.1051/medsci/2020006

Mazieres J, Cropet C, Montané L, Barlesi F, Souquet P, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Jaffro M, Collot S, Ferretti G, Tiffon C, Mahier-Ait Oukhatar C, Blay J Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann. Oncol.. 2020;31(2):289-294. doi:10.1016/j.annonc.2019.10.022

Pasquier D, Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Petit A, Mouret-Reynier M, Goncalves A, Dalenc F, Deluche E, Fresnel J, Augereau P, Ferrero J, Geffrelot J, Fumet J-D, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Mouttet-Audouard R, Bachelot T, Courtinard C Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. Eur. J. Cancer. 2020;125. doi:10.1016/j.ejca.2019.11.001

Bronkhorst A, Ungerer V, Diehl F, Anker P, Dor Y, Fleischhacker M, Gahan P, Hui L, Holdenrieder S, Thierry A Towards systematic nomenclature for cell-free DNA. Hum Genet. Oct 29, 2020. doi:10.1007/s00439-020-02227-2

Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget J-P The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2020;34(5):1315-1328. doi:10.1038/s41375-019-0677-4

Saksouk N, Hajdari S, Perez Y, Pratlong M, Barrachina C, Graber C, Zavoriti A, Sarrazin A, Pirot N, Noël J-Y, Khellaf L, Fabbrizio E, Julien E, Cammas F The mouse HP1 proteins are essential for preventing liver tumorigenesis. Oncogene. 2020;39(13):2676-2691. doi:10.1038/s41388-020-1177-8

Alame M, Cornillot E, Cacheux V, Tosato G, Four M, Oliveira L, Gofflot S, Delvenne P, Turtoi E, Cabello-Aguilar S, Nishiyama M, Turtoi A, Martineau V, Colinge J The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. 2020;10(10):4383-4394. doi:10.7150/thno.42986

Bastid J, Dejou C, Docquier A, Bonnefoy N The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.00718

Blateau P, Coyaud E, Ducros V, Chauchard G, Vendrell J, Solassol J TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma. Cancers (Basel). 2020;12(8). doi:10.3390/cancers12082224

Samalin E, Adenis A TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?. Lancet Oncol.. Jul 16, 2020. doi:10.1016/S1470-2045(20)30337-5

Khashper A, Addley H, Abourokbah N, Nougaret S, Sala E, Reinhold C T2-Hypointense Adnexal Lesions: An Imaging Algorithm. Radiographics. 2020;40(4):1200. doi:10.1148/rg.2020204005

Deshayes E, Piron L, Bouvier A, Lapuyade B, Lermite E, Vervueren L, Laurent C, Pinaquy J-B, Chevallier P, Dohan A, Rode A, Sengel C, Guillot C, Guiu B Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colo-rectal liver metastases. BMC Cancer. 2020;20(1):574. doi:10.1186/s12885-020-07065-z

Mangeat T, Gracia M, Martineau P, Robert B Stratégies de ciblage spécifique de la tumeur fondées sur les caractéristiques des antigènes tumoraux et du microenvironnement tumoral. 2020;36.

Samalin E, Fouchardière C, Boige V, Senellart H, Guimbaud R, Galais M-P, Lièvre A, Seitz J-F, Metges J-P, Bouché O, Boissière-Michot F, Lopez-Crapez E, Bibeau F, Ho-Pun-Cheung A, Ychou M, Adenis A, Di Fiore F, Mazard T Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). Clin Colorectal Cancer. May 15, 2020. doi:10.1016/j.clcc.2020.04.008

Jha P, P?der L, Bourgioti C, Bharwani N, Lewis S, Kamath A, Nougaret S, Soyer P, Weston M, Castillo R, Kido A, Forstner R, Masselli G Society of Abdominal Radiology (SAR) and European Society of Urogenital Radiology (ESUR) joint consensus statement for MR imaging of placenta accreta spectrum disorders. Eur Radiol. 2020;30(5):2604-2615. doi:10.1007/s00330-019-06617-7

Cabello-Aguilar S, Alame M, Kon-Sun-Tack F, Fau C, Lacroix M, Colinge J SingleCellSignalR: inference of intercellular networks from single-cell transcriptomics. Nucleic Acids Res.. Mar 20, 2020. doi:10.1093/nar/gkaa183

Glehen O, Guilloit J-M, Bereder J-M, Lorimier G, Thibaudeau E, Ghouti L, Pinto A, Tuech J-J, Kianmanesh R, Carretier M, Marchal F, Arvieux C, Brigand C, Meeus P, Rat P, Durand-Fontanier S, Mariani P, Lakkis Z, Loi V, Pirro N, Sabbagh C, Texier M, Elias D Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol.. Jul 24, 2020. doi:10.1016/S1470-2045(20)30322-3

Thierry A SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure. Clin. Sci.. 2020;134(12):1295-1300. doi:10.1042/CS20200531

Cohen R, Bennouna J, Meurisse A, Tournigand C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol M-L, Svrcek M, Vernerey D, Menu Y, André T RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J Immunother Cancer. 2020;8(2):e001499. doi:10.1136/jitc-2020-001499

Heudel P, Delaloge S, Parent D, Madranges N, Levy C, Dalenc F, Brain E, Uwer L, Augereau P, Mailliez A, Perrin C, Sablin M-P, Mouret-Reynier M-A, Vermeulin T, Eymard J-C, Petit T, Ferrero J-M, Ilie S, Goncalves A, Chenuc G, Robain M Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study. Anticancer Res.. 2020;40(7):3905-3913. doi:10.21873/anticanres.14381



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés